Literature DB >> 14688088

Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Bing Ren1, Alexander J Szalai, Susan K Hollingshead, David E Briles.   

Abstract

Streptococcus pneumoniae infection is a frequent cause of pneumonia, otitis media, meningitis, and septicemia. Pneumococcal surface protein A (PspA) is an important virulence factor on the pathogen surface, and it is known to interfere with complement activation. In this study, flow cytometry was used to study the effects of PspA and antibodies to PspA on the deposition of complement C3 on the surface of a capsular type 3 strain, WU2, and its PspA- mutant, JY1119. Using naive mouse serum as a complement source, measurable deposition of C3 was observed within 4 min on PspA- pneumococci, and the amount of surface-bound C3 accumulated rapidly as the amount of serum was increased. In contrast, very little C3 was deposited on the PspA+ strain. In nonimmune mouse serum, the classical pathway was the dominant activation pathway triggered by PspA- pneumococci. Accordingly, EGTA blocked almost all of the complement activation. Moreover, a significant amount of C3 was still deposited on the PspA- strain when serum from factor B-deficient mice was used. This deposition was not observed on the PspA+ pneumococci, indicating that PspA may inhibit complement deposition via the classical pathway. Furthermore, under the conditions we tested, PspA also inhibited C3 deposition when the classical pathway was initiated by antibodies to capsular polysaccharide. Antibodies to PspA could overcome the anticomplementary effect of PspA, allowing for increased complement activation and C3 deposition onto PspA+ bacteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688088      PMCID: PMC344006          DOI: 10.1128/IAI.72.1.114-122.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  C3 as substrate for adhesion of Streptococcus pneumoniae.

Authors:  B L Smith; M K Hostetter
Journal:  J Infect Dis       Date:  2000-07-19       Impact factor: 5.226

Review 2.  Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.

Authors:  D M Musher
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

3.  Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene.

Authors:  J Yother; G L Handsome; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

4.  Genetic control of the susceptibility to pneumococcal infection.

Authors:  D E Briles; J Horowitz; L S McDaniel; W H Benjamin; J L Claflin; C L Booker; G Scott; C Forman
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

5.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.

Authors:  D E Briles; J Yother; L S McDaniel
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

7.  The biochemistry of opsonization: central role of the reactive thiolester of the third component of complement.

Authors:  M K Hostetter; R A Krueger; D J Schmeling
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

8.  The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.

Authors:  A Brooks-Walter; D E Briles; S K Hollingshead
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

9.  Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.

Authors:  S L Newman; L K Mikus
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

10.  Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

Authors:  L S McDaniel; J Yother; M Vijayakumar; L McGarry; W R Guild; D E Briles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more
  79 in total

1.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Effect of apolactoferrin on experimental pneumococcal otitis media.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Sebahatin Cureoglu; Patricia A Ferrieri; David E Briles; Michael M Paparella; Steven K Juhn
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

3.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

4.  Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae.

Authors:  Ana Paula Mattos Arêas; Maria Leonor Sarno Oliveira; Eliane Namie Miyaji; Luciana Cezar Cerqueira Leite; Paulo Lee Ho
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice.

Authors:  Lisa R Quin; Quincy C Moore; Larry S McDaniel
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

6.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 7.  The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

9.  Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Authors:  Adriana T Moreno; Maria Leonor S Oliveira; Daniela M Ferreira; Paulo L Ho; Michelle Darrieux; Luciana C C Leite; Jorge M C Ferreira; Fabiana C Pimenta; Ana Lúcia S S Andrade; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

10.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.